Clinical TrialsSepterna has initiated dosing in the Phase 1 trial of SEP-631, marking its return to clinical-stage status.
Financial OutlookSepterna received the $195M upfront payment in connection with the effectiveness of the global collaboration and license agreement and expects to recognize revenue for this upfront payment over the anticipated duration of the company’s participation in the R&D programs.
Strategic PartnershipsThe global collaboration and license agreement between Septerna and Novo Nordisk A/S became effective, initiating joint research and development efforts to discover, develop, and commercialize multiple potential oral small molecule therapies for obesity, type 2 diabetes, and other cardiometabolic diseases.